LEVETIRACETAM- levetiracetam tablet, film coated

देश: संयुक्त राज्य

भाषा: अंग्रेज़ी

स्रोत: NLM (National Library of Medicine)

सक्रिय संघटक:

LEVETIRACETAM (UNII: 44YRR34555) (LEVETIRACETAM - UNII:44YRR34555)

थमां उपलब्ध:

Camber Pharmaceuticals, Inc.

INN (इंटरनेशनल नाम):

LEVETIRACETAM

रचना:

LEVETIRACETAM 250 mg

प्रशासन का मार्ग:

ORAL

प्रिस्क्रिप्शन प्रकार:

PRESCRIPTION DRUG

चिकित्सीय संकेत:

Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older.  Levetiracetam tablets are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. Levetiracetam tablets are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. Levetiracetam tablets are contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions ( 5.4)] . Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), including levetiracetam, during pregnancy. Encourage women who are taking levetiracetam during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/.  Risk Summary Prolonged experience with levetiracetam in pregnant women has not identified a drug-associated risk of major birth defects or miscarriage, based on published literature, which includes data from pregnancy registries and reflects experience over two decades [see Human Data]. In animal studies, levetiracetam produced developmental toxicity (increased embryofetal and offspring mortality, increased incidences of fetal structural abnormalities, decreased embryofetal and offspring growth, neurobehavioral alterations in offspring) at doses similar to human therapeutic doses [see Animal Data].  In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.  Clinical Considerations   Levetiracetam blood levels may decrease during pregnancy [see Warnings and Precautions ( 5.11)] .  Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester. Dose adjustments may be necessary to maintain clinical response.  Data  Human Data   While available studies cannot definitively establish the absence of risk, data from the published literature and pregnancy registries have not established an association with levetiracetam use during pregnancy and major birth defects or miscarriage. Animal Data   When levetiracetam (0, 400, 1200, or 3600 mg/kg/day) was administered orally to pregnant rats during the period of organogenesis, reduced fetal weights and increased incidence of fetal skeletal variations were observed at the highest dose tested. There was no evidence of maternal toxicity. The no-effect dose for adverse effects on embryofetal developmental in rats (1200 mg/kg/day) is approximately 4 times the maximum recommended human dose (MRHD) of 3000 mg on a body surface area (mg/m 2 ) basis.  Oral administration of levetiracetam (0, 200, 600, or 1800 mg/kg/day) to pregnant rabbits during the period of organogenesis resulted in increased embryofetal mortality and incidence of fetal skeletal variations at the mid and high dose and decreased fetal weights and increased incidence of fetal malformations at the high dose, which was associated with maternal toxicity. The no-effect dose for adverse effects on embryofetal development in rabbits (200 mg/kg/day) is approximately equivalent to the MRHD on a mg/m 2  basis.  Oral administration of levetiracetam (0, 70, 350, or 1800 mg/kg/day) to female rats throughout pregnancy and lactation led to an increased incidence of fetal skeletal variations, reduced fetal body weight, and decreased growth in offspring at the mid and high doses and increased pup mortality and neurobehavioral alterations in offspring at the highest dose tested. There was no evidence of maternal toxicity. The no-effect dose for adverse effects on pre- and postnatal development in rats (70 mg/kg/day) is less than the MRHD on a mg/m 2 basis.  Oral administration of levetiracetam to rats during the latter part of gestation and throughout lactation produced no adverse developmental or maternal effects at doses of up to 1800 mg/kg/day (6 times the MRHD on a mg/m 2 basis).  Risk Summary Levetiracetam is excreted in human milk. There are no data on the effects of levetiracetam on the breastfed infant, or the effects on milk production.  The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for levetiracetam and any potential adverse effects on the breastfed infant from levetiracetam or from the underlying maternal condition.  The safety and effectiveness of levetiracetam for the treatment of partial-onset seizures in patients 1 month to 16 years of age have been established [see Clinical Pharmacology ( 12.3) and Clinical Studies ( 14.1)] . The dosing recommendation in these pediatric patients varies according to age group and is weight-based [see Dosage and Administration ( 2.2)] . The safety and effectiveness of levetiracetam as adjunctive therapy for the treatment of myoclonic seizures in adolescents 12 years of age and older with juvenile myoclonic epilepsy have been established [see Clinical Studies ( 14.2)] . The safety and effectiveness of levetiracetam as adjunctive therapy for the treatment of primary generalized tonic-­clonic seizures in pediatric patients 6 years of age and older with idiopathic generalized epilepsy have been established [see Clinical Studies ( 14.3)] . Safety and effectiveness for the treatment of partial-onset seizures in pediatric patients below the age of 1 month; adjunctive therapy for the treatment of myoclonic seizures in pediatric patients below the age of 12 years; and adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in pediatric patients below the age of 6 years have not been established. A 3-month, randomized, double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of levetiracetam as adjunctive therapy in 98 (levetiracetam N=64, placebo N=34) pediatric patients, ages 4 to 16 years old, with partial seizures that were inadequately controlled. The target dose was 60 mg/kg/day. Neurocognitive effects were measured by the Leiter-R Attention and Memory (AM) Battery, which measures various aspects of a child's memory and attention. Although no substantive differences were observed between the placebo and drug treated groups in the median change from baseline in this battery, the study was not adequate to assess formal statistical non-inferiority of the drug and placebo. The Achenbach Child Behavior Checklist (CBCL/6 to 18), a standardized validated tool used to assess a child’s competencies and behavioral/emotional problems, was also assessed in this study. An analysis of the CBCL/6 to 18 indicated on average a worsening in levetiracetam-treated patients in aggressive behavior, one of the eight syndrome scores [see Warnings and Precautions ( 5.1)] . Juvenile Animal Toxicity Data Studies of levetiracetam in juvenile rats (dosed on postnatal days 4 through 52) and dogs (dosed from postnatal weeks 3 through 7) at doses of up to 1800 mg/kg/day (approximately 7 and 24 times, respectively, the maximum recommended pediatric dose of 60 mg/kg/day on a mg/m 2 basis) did not demonstrate adverse effects on postnatal development. There were 347 subjects in clinical studies of levetiracetam that were 65 and over. No overall differences in safety were observed between these subjects and younger subjects. There were insufficient numbers of elderly subjects in controlled trials of epilepsy to adequately assess the effectiveness of levetiracetam in these patients. Levetiracetam is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Clinical Pharmacology ( 12.3)] . Clearance of levetiracetam is decreased in patients with renal impairment and is correlated with creatinine clearance [see Clinical Pharmacology ( 12.3)] . Dose adjustment is recommended for patients with impaired renal function and supplemental doses should be given to patients after dialysis [see Dosage and Administration ( 2.5)].

उत्पाद समीक्षा:

Levetiracetam tablets USP, 250 mg are blue colored, oblong shaped, scored, film coated tablets debossed with 'H' on one side and '87' on other side. They are supplied in containers of 30 tablets                           (NDC 31722-536-30) 60 tablets                           (NDC 31722-536-60) 120 tablets                         (NDC 31722-536-12) 500 tablets                         (NDC 31722-536-05) 1000 tablets                      (NDC  31722-536-10) Levetiracetam tablets USP, 500 mg are yellow colored, oblong shaped, scored, film coated tablets debossed with  'H'  on one side and '88' on other side. They are supplied in containers of 30 tablets                          (NDC  31722-537-30) 60 tablets                          (NDC  31722-537-60) 120 tablets                        (NDC  31722-537-12) 500 tablets                        (NDC  31722-537-05) 1000 tablets                     (NDC  31722-537-10) Levetiracetam tablets USP, 750 mg are orange colored, oblong shaped, scored, film coated tablets debossed with  'H'  on one side and '90' on other side. They are supplied in containers of 30 tablets                           (NDC  31722-538-30) 60 tablets                           (NDC  31722-538-60) 120 tablets                         (NDC  31722-538-12) 500 tablets                         (NDC  31722-538-05) Levetiracetam tablets USP, 1000 mg are white colored, oblong shaped, scored, film coated tablets debossed with  'H'  on one side and '91' on other side. They are supplied in containers of 30 tablets                           (NDC  31722-539-30) 60 tablets                           (NDC  31722-539-60) 120 tablets                         (NDC  31722-539-12) 500 tablets                         (NDC  31722-539-05) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

प्राधिकरण का दर्जा:

Abbreviated New Drug Application

सूचना पत्रक

Camber Pharmaceuticals, Inc.
----------
MEDICATION GUIDE
Levetiracetam Tablets, USP
(lee" ve tye ra' se tam) for oral use
Read this Medication Guide before you start taking levetiracetam
tablets and each time you get a refill. There
may be new information. This information does not take the place of
talking to your healthcare provider
about your medical condition or treatment.
What
is
the
most
important
information
I
should
know
about
levetiracetam
tablets?
Like other antiepileptic drugs, levetiracetam tablets may cause
suicidal thoughts or actions in a very small
number
of
people,
about
1
in
500
people
taking
them.
Call a healthcare provider right away if you have any of these
symptoms, especially if they are new, worse,
or
worry
you:
• thoughts
about
suicide
or
dying
• attempts
to
commit
suicide
• new
or
worse
depression
• new
or
worse
anxiety
• feeling
agitated
or
restless
• panic
attacks
• trouble
sleeping
(insomnia)
• new
or
worse
irritability
• acting
aggressive,
being
angry,
or
violent
• acting
on
dangerous
impulses
• an
extreme
increase
in
activity
and
talking
(mania)
• other
unusual
changes
in
behavior
or
mood
Do
not
stop
levetiracetam
tablets
without
first
talking
to
a
healthcare
provider.
• Stopping levetiracetam tablets suddenly can cause serious
problems. Stopping a seizure medicine suddenly
can
cause
seizures
that
will
not
stop
(status
epilepticus).
• Suicidal thoughts or actions can be caused by things other than
medicines. If you have suicidal thoughts or
actions,
your
healthcare
provider
may
check
for
other
causes.
How
can
I
watch
for
early
symptoms
of
suicidal
thoughts
and
actions?
• Pay attention to any changes, especially sudden changes, in mood,
behaviors, thoughts, or feelings.
• Keep
all
follow-up
visits
with
your
healthcare
provider
as
scheduled.
Call your healthcare provider between visits as needed, especially if
you are worried about symptoms.
What
are
levetiracetam
tablets?
Levetiracetam tablets are a prescription medicine taken by mouth that
is used to

उत्पाद विशेषताएं

LEVETIRACETAM - LEVETIRACETAM TABLET, FILM COATED
CAMBER PHARMACEUTICALS, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LEVETIRACETAM TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
LEVETIRACETAM TABLETS.
LEVETIRACETAM TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1999
RECENT MAJOR CHANGES
Warnings and Precautions ( 5.6) 3/2024
INDICATIONS AND USAGE
Levetiracetam tablets are indicated for the treatment of partial-onset
seizures in patients 1 month of age
and older ( 1.1)
Levetiracetam tablets are indicated for adjunctive therapy for the
treatment of:
• Myoclonic seizures in patients 12 years of age and older with
juvenile myoclonic epilepsy ( 1.2)
• Primary generalized tonic-clonic seizures in patients 6 years of
age and older with idiopathic generalized
epilepsy ( 1.3)
DOSAGE AND ADMINISTRATION
• Use the oral solution for pediatric patients with body weight ≤
20 kg ( 2.1)
• For pediatric patients, use weight-based dosing for the oral
solution with a calibrated measuring device
(not a household teaspoon or tablespoon) ( 2.1)
Partial-Onset Seizures (monotherapy or adjunctive therapy)
• 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg
twice daily every 2 weeks to
recommended dose of 21 mg/kg twice daily ( 2.2)
• 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg
twice daily every 2 weeks to
recommended dose of 25 mg/kg twice daily ( 2.2)
• 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg
twice daily every 2 weeks to
recommended dose of 30 mg/kg twice daily ( 2.2)
• Adults 16 Years and Older: 500 mg twice daily; increase by 500 mg
twice daily every 2 weeks to a
recommended dose of 1500 mg twice daily ( 2.2)
Myoclonic Seizures in Adults and Pediatric Patients 12 Years and Older
• 500 mg twice daily; increase by 500 mg twice daily every 2 weeks
to recommended dose of 1500 mg
twice daily ( 2.3)
Primary Generalized Tonic-Clonic Seizures
• 6 Years to < 16 Years